Simcere Pharmaceutical Group Ltd. and Boehringer Ingelheim have entered into a global license and collaboration agreement to develop SIM0709, a pre-clinical bispecific antibody designed to treat inflammatory bowel disease (IBD), a chronic and debilitating condition affecting millions worldwide. The partnership reflects a shared ambition to address persistent unmet needs in IBD, where many patients continue to experience disease progression despite existing therapies.
IBD, which includes conditions such as Crohn’s disease and ulcerative colitis, is estimated to affect more than three million people globally. The disease is lifelong and progressive, often leading to repeated hospitalizations, invasive surgeries, and a substantial decline in quality of life. While several anti-inflammatory and biologic treatments are available, none can fully prevent long-term complications or halt disease progression in all patients, underscoring the need for new therapeutic approaches.
SIM0709 is a long-acting, humanized bispecific antibody developed by Simcere using its proprietary multi-specific antibody platform. The investigational therapy simultaneously targets two key drivers of intestinal inflammation: tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23). By blocking both pathways, SIM0709 is designed to interfere with the initiation and progression of IBD more effectively than therapies aimed at a single target.
According to Simcere, preclinical studies have shown promising results. In both in vitro primary cell experiments and in vivo animal models, SIM0709 demonstrated strong synergistic efficacy and outperformed the combination of two separate monotherapies targeting the same pathways. These findings suggest the bispecific approach could offer enhanced therapeutic benefit compared with existing treatment strategies.
Boehringer Ingelheim highlighted the continued burden faced by IBD patients despite current treatment options. Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim, said many patients still experience severe complications and disease progression, adding that the collaboration aims to accelerate development of a potentially life-changing therapy.
From Simcere’s perspective, the partnership brings global development expertise to a compound with first-in-class potential. Gaobo Zhou, Chief Investment Officer at Simcere Pharmaceutical Group, noted that working with Boehringer Ingelheim’s immunology capabilities positions SIM0709 for rigorous international clinical development.
Under the agreement, Boehringer Ingelheim receives global rights to SIM0709 outside of Greater China. Simcere is eligible to receive an upfront payment, along with development, regulatory, and sales milestone payments totaling up to €1.058 billion, as well as royalties on net sales outside Greater China.
The deal marks Simcere’s second out-licensing transaction in the autoimmune space. As of January 2026, the company has completed five out-licensing agreements for internally developed drug technologies, with total potential transaction values of approximately $4.6 billion, highlighting its growing role as a global innovation partner in biopharmaceutical research.